These small cap ASX shares are on the rise today

The All Ordinaries (Index: ^AXAO) (ASX: XAO) may have returned to form today with a solid gain, but this pales in comparison to some of the gains being made at the small end of the market.

Here’s why these small cap shares are on the rise today:

The Imugene Limited (ASX: IMU) share price has jumped 9% to 2.4 cents after the clinical stage immuno-oncology company announced that it has completed the recruitment for its Phase 1b clinical trial of the HER-Vaxx cancer vaccine in HER-2 gastric cancer patients. The ongoing trial is testing three different doses in combination with current standard of care chemotherapy Cisplatin and either Fluorouracil or Capecitabine. Management expects to complete the analysis in the coming months before establishing the optimal dose for a larger Phase 2 study. This is positive news but a little soon to invest in my opinion.

The Medlab Clinical Ltd (ASX: MDC) share price has risen almost 7% to 48 cents after advising that it has received a licence to export cannabis from the Office of Drug Control in Canberra. The licence relates to its two cannabis-based medicines, NanaBis and NanaBidial. Both products utilise Medlab’s patented NanoCelle delivery platform which allows the delivery of nano particles of the active pharmaceutical ingredients into the side of the cheek. The company is targeting the chronic disease market.

The Slater & Gordon Limited (ASX: SGH) share price has zoomed 14% higher to $2.80 after the embattled law firm announced its Get Your Super Back campaign. Slater and Gordon aims to bring big bank-owned super funds to account, saying the funds owe Australians more than one billion dollars. The law firm indicated that Commonwealth Bank of Australia (ASX: CBA) owned Colonial First State and struggling financial services company AMP Limited (ASX: AMP) are likely to be the first targets in a series of legal actions.

ASX Tech Share – Real Winner from the World Cup

Earlier this year, millions of Australians set alarms and watched the world's biggest sporting event, the World Cup, play out. But did you know there was another Australian representative quietly succeeding as the world watched?

It's the start-up who have positioned themselves as the global leader in sports analytics. Motley Fool's resident tech expert has already upgraded the recommendation of this company's stock to a rating of simply "Buy More".

Click here to access this share. It's completely FREE!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.